Covid-19 roundup: Novartis treatment comes up short in PhIII; Humanigen expands trial, but draws criticism
A major player trying to adapt an anti-inflammatory for Covid-19 has seen the drug fall flat.
Novartis reported Friday that …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
